Incidence, clinical correlates, timing of occurrence, and consequences of acute thrombus formation in patients undergoing the MitraClip procedure.
Despite adequate heparinization, there are case reports documenting fresh intracardiac thrombus formation during the MitraClip procedure. To evaluate the incidence and clinical consequences of intracardiac thrombus formation during MitraClip implantation. The clinical data and transesophageal echocardiography (TEE) recorded during 100 consecutive MitraClip procedures (81 males, mean age 67.8 [8.3] years) were reviewed. In all patients heparin bolus was given immediately after successful transseptal puncture, and the ACT was maintained > 250 seconds throughout the procedure. Thrombus formation during the procedure was documented in 9 patients (9%). In 6 patients thrombi formed on the transseptal needle/sheath (2 attached to the transseptal sheath in the right atrium and 4 on the transseptal sheath immediately after puncture in the left atrium) and in 3 patients on the MitraClip device itself in the left atrium (2 on the steerable guiding catheter, and 1 on the clip delivery system). Overall, 6 (67%) thrombi formed prior to heparin administration and 3 (33%) after heparin with ACT > 250s. All thrombi were transient and disappeared within minutes. There were no periprocedural ischemic strokes, transient ischemic attacks, or other embolic complications. Patients with thrombi had similar baseline clinical characteristics except for lower ejection fraction (EF: 23 [10%] vs 30 [10%]; p=0.03). Overall, 6 out of 100 patients died in hospital post-procedure: 2 out of 9 with visible thrombus (1 due to electric storm on day 14 and 1 due to cardiogenic shock on day 5) and 4 out of 91 without thrombus (p=0.09). Periprocedural thrombi occur relatively often during the MitraClip procedure, especially in patients with a low LVEF, but are transient.